BRIGHT MINDS BIOSCIENCES INC.
DRUGNasdaq
$76.12
↑ +2.5%Jul 17 close · end-of-day
Price
1Y↑ +206.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Bright Minds Biosciences Inc. develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
- CEO
- Ian B. McDonald
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- New York
- Website
- brightmindsbio.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
May 21, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-28 | Cormorant Asset Management, LLC | Sale | 109,331 | $89.50 | $9.8M | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.